NxStage Medical's third-quarter results continued the company's trends toward improvement. Revenue climbed 6% to $92 million, which was above its previous guidance for $89 million to $91 million in ...

NxStage Medical, Inc. NXTM recently announced the regulatory approval of its System One platform by the FDA for solo home hemodialysis treatment. The company has also announced that it will provide ...

NxStage Medical, Inc. NXTM recently announced that its subsidiary NxStage Kidney Care is partnering Dialyze Direct for supporting the needs of patients who need on-site skilled-nursing facilities (SNF ...

NxStage Medical (NASDAQ: NXTM) has revolutionized the way that dialysis patients receive treatment, with its home-dialysis devices offering a much more convenient alternative to visiting outpatient ...

It's been more than a year since NxStage Medical (NXTM +0.00%) accepted an acquisition bid from Fresenius Medical Care (FMS +0.11%). Investors have looked forward to the $30 per share in cash that ...

NxStage Medical (NASDAQ: NXTM) is in an awkward position right now, and it's one that any investor in a company that has received an acquisition bid can understand. The maker of home dialysis ...

NxStage Medical Inc., a medical device maker based in Lawrence, is expanding its business to offer kidney dialysis treatment at clinics in Massachusetts. NxStage’s core business is making kidney ...

Please provide your email address to receive an email when new articles are posted on . Dialysis product manufacturer NxStage Medical is part of a team of device makers that won a contract from the ...

NxStage Medical (NASDAQ: NXTM) has been in limbo since mid-2017, when it received an offer from Fresenius Medical Care (NYSE: FMS) to buy the company. Since then, shares of NxStage have stayed ...